Brainsway reports Q1 EPS 2c vs. 0c last year

Reports Q1 revenue $11.5M vs. $9.1M last year. “We continued to rapidly increase our share of the TMS market during the first quarter of 2025. The momentum in our business is being driven by growing demand and utilization of our industry-leading technology in multiple indications, including obsessive compulsive disorder and anxious depression, as well as enhanced global sales channels. Importantly, we continue to gain traction with large enterprise customers, resulting in the opportunity for meaningful recurring revenue and a significant sales backlog,” said Hadar Levy, BrainsWay’s (BWAY) CEO. “We see tremendous opportunities for future growth with several upcoming key catalysts, including our next-generation Deep TMS 360 system, the expansion into new indications, and broadened and enhanced accessibility across indications supported by additional clinical data. In order to leverage these critical technology advancements, our global market presence continues to expand, and now extends across key markets including Canada, Asia, India and Europe,” concluded Mr. Levy.